ReviewFrontiers in molecular biosciences2026
Histone methyltransferase SMYD1: playing a crucial role in disease progression.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcript isoform switching during embryonic and post-hatch development of broiler breast muscle.Poultry science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histone methyltransferase SET and MYND domain-containing 1 (SMYD1), a member of the SMYD family, catalyzes the methylation of lysine residues on histone proteins. This modification is pivotal in regulating chromatin structure and gene expression, influencing processes such as cell proliferation, differentiation, and development. Primarily expressed in muscle tissues, SMYD1 plays a crucial role in muscle development and function. However, accumulating evidence suggests its involvement in the progression of various diseases, including cancer, cardiovascular diseases, and metabolic disorders. By modulating key signaling pathways and gene expression profiles, SMYD1 affects cellular processes such as cell cycle regulation, apoptosis, and inflammation. This review aims to explore the multifaceted roles of SMYD1 in disease progression, highlighting its potential as a therapeutic target. Understanding the molecular mechanisms underlying the effects of SMYD1 will be essential for developing strategies to manipulate its activity for disease prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.